IL17A and colitis: Previous studies demonstrated that the development of DSS-induced colitis was enhanced by the administration of an anti-IL-17 neutralizing monoclonal antibody, which suggests that IL-17 plays an anti-inflammatory role in mediating the initiation and progression of inflammation in DSS colitis [9].